HortenseFouilland

Associate

Paris + 33.1.56.59.38.76

Connect:

Share

Hortense Fouilland's practice focuses on venture capital, private equity, M&A, and capital markets. She assists high-growth companies, both listed and unlisted, their managers, and private equity and industrial investors in all operations and at every stage of development, from entrepreneurial start-ups to global corporations. She also has experience in mid-cap and large-cap leveraged buyout (LBO) transactions.

Experience

  • Deezer merges with and into I2PO S.A.Jones Day is advising Deezer S.A. in the context of the proposed SPAC transaction whereby Deezer S.A. would be merged with and into I2PO S.A., a French SPAC listed on the professional segment of the regulated market of Euronext Paris and the related PIPE financing.
  • Nauta Capital and Orange Ventures invest in YZRJones Day advised Nauta Capital and Orange Ventures in the $12 million Series A financing of YZR, a French start-up that uses AI to normalize data.
  • New Alpha Asset Management and Open CNP lead €10 million financing of ClimbJones Day advised New Alpha Asset Management and Open CNP in the €10 million Series A financing round of Climb (formerly known as Tacotax), a financial platform that has already helped more than 800,000 people in France better manage their taxes and investments.
  • Snapshift raises $45 million in Series A roundJones Day advised Snapshift, the French SaaS HR application for businesses in the hospitality and retail sector, in its $45 million Series A financing round led by Highland Europe.
  • Elaia Partners leads $9.2 million Series A financing round of IndeezJones Day advised Elaia Partners in connection with leading the $9.2 million Series A financing of Indeez, the fastest growing European insurtech for platform workers.
  • Omnes Capital, Merieux Equity Partners, and Elaia Partners participate in €20 million financing round of SeqOne GenomicsJones Day advised Omnes Capital, Merieux Equity Partners, and Elaia Partners in the €20 million financing round of SeqOne Genomics, a French-based provider of next genomic analysis solutions for personalized medicine.
  • EagleTree Capital acquires Andronaco IndustriesJones Day advised EagleTree Capital in the acquisition and financing of Andronaco Industries, a leading provider of corrosion-resistant flow control technologies.
  • Elaia Partners and Bpifrance lead €5 million seed investment in ContinuityJones Day represented Elaia Partners and Bpifrance in connection with a €5 million seed investment in Continuity, the company using AI to help insurers improve underwriting for small and mid-size enterprises.
  • Lifen raises $58 million in Series C financing roundJones Day represented Lifen, a French-based company that develops and operates a global communication platform to facilitate collaboration among physicians, in connection with a $58 million Series C round of financing led by Creadev and Lauxera Capital Partners.
  • Elaia Partners leads €6 million financing round of ElevoJones Day represented Elaia Partners in connection with the €6 million financing round of Elevo, the people management platform that increases the employee experience and enables people leaders to develop engaged and high performing teams.
  • ManoMano completes $355 million Series F financing roundJones Day represented ManoMano, an online marketplace specializing in the sale of DIY, home improvement, and gardening products, in connection with its $355 million Series F round of financing led by Dragoneer Investment Group with the participation of existing investors Temasek, General Atlantic, Eurazeo, Bpifrance, Aglaé Ventures, Kismet Holdings, and Armat Group.
  • 360Learning raises $200 million in financing roundJones Day advised 360Learning, a French-based company having developed a collaborative learning SaaS platform to help companies unlock learning based on collective expertise, in connection with its $200 million round of financing led by Sumeru, Silver Lake, and Softbank.
  • Elaia Partners leads €4 million financing round of Mablink BioscienceJones Day represented Elaia Partners in connection with the €4 million seed round of financing of Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug-linker PSARlink™ platform.
  • Unseenlabs raises €20 million in Series B funding roundJones Day advised Unseenlabs, a European leader in satellite radio frequency (RF) geolocation of ships at seas, in connection with its €20 million Series B round of financing.
  • HealthHero acquires QareJones Day advised HealthHero in its acquisition of Qare, a French platform that provides medical video consultation services, backed by Kamet Ventures.
  • Nanobiotix completes $113.3 million IPO on NasdaqJones Day represented Nanobiotix S.A., a French clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, in connection with its $113.3 million initial public offering in the United States and listing on Nasdaq.
  • IntegraGen’s shareholders sell majority interest to OncoDNA in tender offerJones Day advised IntegraGen, a biotechnology company developing molecular markers for central nervous system and metabolic diseases, in connection with the public tender offer of shares by OncoDNA, a private health technology and precision medicine company focused on oncology.
  • Elaia Partners participates in €2 million financing of Honing BiosciencesJones Day represented Elaia Partners in connection with the €2 million financing of Honing Biosciences, a French bio-therapeutics company that develops and improves cell-based therapies.
  • European growth VC investor participates in €12.5 million financing round of AlmaJones Day assisted a European growth VC investor in connection with the €12.5 million financing round of Alma, a French fintech which simplified installment payments for e-commerce and in-store merchants.
  • Pharnext raises €7.7 million in private placementJones Day represented Pharnext SA, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on its PLEOTHERAPY artificial intelligence platform harnessing big genomics data and network pharmacology, in connection with its €7.7 million private placement of 1,799,061 of new Ordinary Shares.
    • View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.